HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 369 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $781,420 | -44.6% | 21,664 | -41.3% | 0.04% | -32.7% |
| Q1 2023 | $1,410,433 | +238.4% | 36,932 | +404.1% | 0.06% | +266.7% |
| Q4 2022 | $416,849 | -59.9% | 7,326 | -71.6% | 0.02% | -62.5% |
| Q4 2021 | $1,039,000 | +5.6% | 25,830 | +9.4% | 0.04% | +29.0% |
| Q1 2021 | $984,000 | +351.4% | 23,600 | +184.3% | 0.03% | +6.9% |
| Q3 2020 | $218,000 | – | 8,300 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,816,162 | $195,784,000 | 9.33% |
| BB BIOTECH AG | 5,846,564 | $57,764,000 | 2.74% |
| QVT Financial LP | 4,556,090 | $45,014,000 | 2.44% |
| Parametrica Management Ltd | 29,578 | $292,000 | 2.21% |
| SECTORAL ASSET MANAGEMENT INC | 4,389,682 | $43,370,000 | 1.84% |
| Belmont Global Advisors, Inc. | 257,000 | $2,539,000 | 1.83% |
| HARVEY CAPITAL MANAGEMENT INC | 394,550 | $3,898,000 | 1.40% |
| Lombard Odier Asset Management (USA) Corp | 1,350,000 | $13,338,000 | 0.70% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 6,199,685 | $61,253,000 | 0.63% |
| Callan Capital, LLC | 199,230 | $1,968,000 | 0.53% |